← Back
Data updated: Jul 17, 2026
HANSAMED INC
Generics Pharmaceuticals
HANSAMED INC is a generic drug manufacturer with 2 FDA-approved products.
2017
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Upcoming FDA Decisions
Full Calendar → Dec 19, 2026 — Imlifidase
Dec 19, 2026 — Imlifidase
HANSAMED INC's Key Drugs
HANSAMED INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
HANSAMED INC's Recent FDA Approvals
New NDA/BLA approvals for HANSAMED INC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
HANSAMED INC's Therapeutic Areas
Disease areas where HANSAMED INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
HANSAMED INC Pipeline Snapshot
Active clinical trials for HANSAMED INC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (2)
Company Info
- First Approval
- 2017-07-11
- Latest
- 2017-07-11
- Applications
- 2